{
    "nctId": "NCT06403904",
    "briefTitle": "Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study",
    "officialTitle": "Assessing Clinical Features and Outcome of Breast Cancer in PALB2",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "The primary endpoint of this trial is to evaluate the frequency of PALB2-related BC in the different European countries, reflecting the real needs for this patients' population.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n- 1. Has a histologically or cytologically confirmed breast cancer 2. Has any stage of BC 3. Has documented mutation in PALB2 gene (germline or somatic) that is predicted to be deleterious or suspected deleterious.\n\n4. Has a multigene test performed and resulted negative for alterations. 5. Has information on tumours characteristics, modality of diagnosis, type of surgical treatment, medical therapy, family history and eventually second primary tumours\n\nDemographics Is male or female, who is at least 18 years of age at the time of signing the informed consent.\n\nExclusion Criteria:\n\nHas a benign variant of PALB2 gene or variant of uncertain (or unknown) significance (VUS) Is involved in the planning and/or conduct of the study Is judged by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n\n-",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}